Better Buy: GlaxoSmithKline vs. Eli Lilly [The Motley Fool]
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: The Motley Fool
GlaxoSmithKline ( NYSE:GSK Eli Lilly NYSE:LLY posted disappointing fourth-quarter results wowed investors with its Q results But the performance over one quarter -- and even over one year -- can be deceiving. What really matters are the long-term prospects for a company. Which of these two big pharma stocks is the better pick for long-term investors? Here's how GlaxoSmithKline and Eli Lilly compare. Image source: Getty Images. The case for GlaxoSmithKline To be sure, GlaxoSmithKline is in a state of transition right now. The drugmaker is dealing with the loss of exclusivity for blockbuster respiratory drug Advair. Sales are also declining for other key drugs, including Relvar/Breo Ellipta and Lamictal. GlaxoSmithKline is also preparing to spin off its consumer business in a joint venture with Pfizer However, the company has several growth drivers for the future. At the top of the list is its vaccine business. Sales continue to soar for shingles vaccine Shingrix. Glaxo's meningitis vac
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GSK plc American Depositary Shares (Each representing two Ordinary Shares) news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- GSK plc (NYSE: GSK) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapseBusiness Wire
- GSK plc (NYSE: GSK) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- GSK plc (NYSE: GSK) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.MarketBeat
GSK
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/16/24 - Form 6-K
- GSK's page on the SEC website